Considering that thalassemia is a autosomal recessive genetic disorder, using a pharmacological approach(if possible at all) to model the disease is methodologically unsound. The generalizability of your drug-induced model will always be questioned. However, if your objective is to study a subset of the thalassemia complications (i.e. microcytic anemia), you may then use a pharmacological approach like iron deprivation etc.